• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1246550 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type, I7 b: h( q, w6 H% B% d; s
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 - Q$ a5 c8 t& C$ N" @* ~
+ Author Affiliations
; R) ^- R) k: c. B) H5 B  ^2 W
9 `3 `$ R" \/ W- ^0 K! N2 u8 I8 I1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 K2 w9 V) P+ Z5 r: Y5 O0 }2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 k9 u0 k4 Y% Q! Y" ]# a9 h$ R
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 R0 y. z% Q: S+ c" s; \% y4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 3 r1 m. a3 d. q4 S( C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. N/ o1 X) c6 s$ H6 `6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
  r" [& t2 Y# t* _) b  {7Kinki University School of Medicine, Osaka 589-8511, Japan
% i" _/ ?# M. y: c" r, G- Z8Izumi Municipal Hospital, Osaka 594-0071, Japan & ~3 a# x  r  S- |% i$ }! C3 _
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 9 l. R0 U5 j8 ]5 t* ]8 ?
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; k8 z: D* }# s2 K
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
  J0 I0 B& [, [/ m, m6 D: P) {2 J" l5 f9 p* W
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
" a7 m9 Z- F+ L) k, J
* a+ q; j  B/ ?& _) dAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato $ ^3 u" t/ B; S9 o  e- {* U2 ~+ ?! h/ w

  o5 k8 z9 ]1 H- G. v; HAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  6 r1 c- I9 n* n; k

7 ~3 c+ j3 ]$ O1 v* EPublished online on: Thursday, December 1, 2011 ; T# F% Y9 o* k) h5 j  M, t
3 E/ H$ H; X; g, r8 v: H/ H3 _$ z# O
Doi: 10.3892/ol.2011.507
9 z! R) C+ k! q  y- _6 j( q( ]* O: Y3 x3 q" e  s
Pages: 405-410 + a2 }9 [& K( V* R

* p3 c+ V# U* ~: m" A1 UAbstract:
% N% p! f  K* j, x/ H" V) k. x9 k) o* }S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.7 v6 `- q6 f: n& Q+ u& i

, |$ B, `# I% r! g
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
7 Y" ^$ d  B; aF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 8 a2 h- M% l5 `& w' t
+ Author Affiliations
: d; t) m. _' \. p1 i( u1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 9 u/ _' t5 r7 ^+ j% q' o' B" o
2Department of Thoracic Surgery, Kyoto University, Kyoto
+ J4 K6 w/ N( K7 o, g1 M6 B) y+ u/ u3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
& O8 j: A: x+ ]+ H6 \& x* A1 _- s&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 8 ~% ~! D2 z6 T) m; K
Received September 3, 2010. 8 \9 w2 m+ O: X! f3 j; p
Revision received November 11, 2010. 9 O- J; Y3 q4 O( ]6 q2 ]
Accepted November 17, 2010.
( [" r+ Y# B# z+ P1 U; ]3 \) fAbstract
. r  d- w6 |% y: bBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
! I1 c$ ?" ]" X" s: e; Y' {# }& B. {3 UPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. & j3 W$ L4 Q; |" @- @* _
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
5 D6 x' `9 ~4 k6 O, c8 h. H# l" \Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
+ L2 @) |9 E+ g
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
8 p8 |1 j$ k; J5 V  j  \今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?9 W+ `  M# J! A3 H
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
$ v( Q) Z7 t9 y+ O* ^! g1 Mhttp://clinicaltrials.gov/ct2/show/NCT01523587
5 |7 r/ \( ~+ x" M  g6 E* z
3 O. j7 I: l) n& F3 C8 ZBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
9 o, v) ^* x! I" ehttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
6 V9 |! k* b, D- v' H- i
0 N: v# k: f: V$ _3 c7 k. x- g* H/ _从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
+ j) W# @1 }, @$ R/ C: m至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 2 w7 G3 U' ^3 D2 q  c
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
2 }/ o1 ~/ x* j  Q至今为止,未出 ...

9 s9 b6 ~. W, z1 B: {1 ~) y没有副作用是第一追求,效果显著是第二追求。
% X- X! c. d0 z/ F4 ?5 i8 H不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表